PharmaSGP Holding SE

Investor Relations

Investor Relations

Welcome to the Investor Relations Portal of PharmaSGP Holding SE, one of the leading German providers of natural OTC and other healthcare products.

The share

Share chart
Basic infomation
Shareholder structure
Analysts

Basic information

ISIN / WKN DE000A2P4LJ5 / A2P4LJ
Ticker Symbol PSG
Type of Shares Existing bearer shares with no-par value
First day of trading June 19, 2020
Number of Shares 12,000,000
Stock Exchanges Frankfurter Wertpapierbörse
Designated Sponsor Joh. Berenberg, Gossler & Co. KG, Neuer Jungfernstieg 20, 20354 Hamburg, Germany
Paying Agent Quirin Privatbank AG, Kurfürstendamm 119, 10711 Berlin, Germany

Charlotte Friedrichs, Joh. Berenberg, Gossler & Co. KG

Company

Company profile
Boards
Financial Key Figures
Nachhaltigkeit
Factsheet

Company profile

PharmaSGP is a pure-play consumer health company with a broad portfolio of leading natural non-prescription pharmaceuticals sold over the counter (“OTC”) and other healthcare products. PharmaSGP’s products are sold exclusively through pharmacies. Its products are based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company’s core brands in the category „Health Brands“ cover chronic indications, including pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic natural pain remedies with its brand families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain. The DESEO® and Neradin® brands are aimed at the men’s health market. While TAUMEA® provides relief from vertigo, Lindaven® helps with haemorrhoids. Our brands in the „Beauty Brands” category include cosmetic anti-ageing preparations.

PharmaSGP has established an asset-light business model that ensures decidedly substantial scalability with a highly efficient cost structure. Years of in-depth regulatory experience make it possible to quickly integrate OTC products of the most diverse categories into the portfolio and launch onto markets. As a D2C specialist, PharmaSGP achieves a very wide coverage among relevant target groups with over 100 million contacts per month – and all this under attractive and efficient media conditions.

Drawing on these strengths, PharmaSGP has been generating continuous and profitable growth of the „Health Brands“ for many years. In 2020 PharmaSGP generated revenues of 63.2 € million at an EBIT margin of 26%.

PharmaSGP's growth strategy aims to make efficient use of the pan-European platform.
On the one hand, PharmaSGP is constantly expanding the number of indications covered by its product range, while on the other, PharmaSGP is pushing expansion within Europe. Apart from the further organic growth of the existing „Health Brands“, PharmaSGP will focus on the acquisition and integration of established brands in future.

First Product Launch
2012
revenues in 2020
63.2
€ Million
AVERAGE ADJUSTED EBIT MARGIN
> 30 %
(2017-2020)

Boards

Management Board

Natalie Weigand

CEO
Natalie Weigand (born 1981) joined the FUTRUE Group as the leader of strategic marketing in 2013, rising to the position of head of marketing and sales. Before the IPO, PharmaSGP was a company of the FUTRUE Group and Ms. Weigand has been CEO of PharmaSGP since 2017. Prior to joining FUTRUE Group and PharmaSGP, Natalie Weigand has worked as a brand and marketing manager at Johnson & Johnson. She is holding a Bachelor of Arts in European Business Administration from Cologne Business School, Germany, and a post-graduate degree in television production.
Curriculum Vitae

Michael Rudolf

CFO

Michael Rudolf (born 1974) joined the FUTRUE Group in 2016 and has been CFO of PharmaSGP since 2017. Prior to joining PharmaSGP, Michael Rudolf has worked at McKinsey & Company, served as head of mergers & acquisitions, portfolio management and corporate projects at Verlagsgruppe Weltbild, and was responsible for investment and portfolio management for digital investments of the Media-Saturn Group. He is holding a Master’s Degree in Business Administration from the University of Mannheim, Germany.

Curriculum Vitae

Supervisory Board

C. Fischer

Dr Clemens Fischer, Head of the Supervisory Board

Dr Clemens Fischer (born 1975) has been Head of the Supervisory Board of PharmaSGP Holding SE since March 4, 2020. Mr. Fischer holds a Doctor of Medicine degree from the Technical University of Munich, a Master of economics degree and a Master of business administration from Harvard Business School. Upon graduation in 2001, Mr. Fischer joined Novartis as a senior project manager, where he eventually became a member of the German executive board for strategy and the cardiovascular unit. In 2007, Mr. Fischer founded the FUTRUE Group, which includes more than 24 subsidiaries worldwide in the pharmaceutical and biotech sectors.

Further mandates: Member of the board of managing directors in 18 companies of the FUTRUE Group.
Curriculum Vitae
Madlena H.

Madlena Hohlefelder, Deputy head of the Supervisory Board

Madlena Hohlefelder (born 1981) has been deputy head of the Supervisory Board of PharmaSGP Holding SE since March 4, 2020. Until 2003, Ms. Hohlefelder studied economics at the University of St. Gallen, Switzerland. She subsequently earned a Master’s degree in legal studies from Ludwig-Maximilian-University, Munich. Upon graduation, Ms. Hohlefelder joined Boston Consulting Group. Afterwards, she joined the FUTRUE Group and co founded most of the entities that today comprise PharmaSGP and the FUTRUE Group. In addition, Ms. Hohlefelder co-founded pharmaceuticals company Naturwohl Pharma GmbH in 2010.

Further mandates: MVH Beteiligungs- und Beratungs-GmbH (member of the board of managing directors)
Curriculum Vitae
Dr Axel Rebien

Dr Axel Rebien

Dr Axel Rebien (born 1971) has been member of the Supervisory Board of PharmaSGP Holding SE since June 1, 2020. In 1999, Dr Rebien graduated from Gottfried Wilhelm Leibniz University in Hannover and obtained a degree in economics. Upon graduation, he joined Arthur Andersen GmbH. In 2005, Dr Rebien joined Tom Tailor GmbH, where he served as Chief Financial Officer. In 2006, Dr Rebien earned a Doctorate in political sciences from the Technical University Chemnitz. In 2010, he became Chief Financial Officer of TOM TAILOR Holding AG. In 2016, Dr. Rebien joined 7 Investment GmbH (now FUTRUE GmbH) as Chief Financial Officer. From 2017 to 2021 he has been Chief Financial Officer of heidelplay Group GmbH. In 2021 he took the office as Chief Executive Officer of Unzer GmbH (formerly heidelpay Group Gmbh) which he has held ever since.

Further mandates: Unzer GmbH (member of the board of managing directors)
Curriculum Vitae

Financial Key Figures

Key financial data 2017* 2018* 2019* Q1 2019** Q1 2020** H1 2019** H1 2020** 9M 2019** 9M 2020**
Revenues (€ million) 53.1 60.6 62.6 15.0 16.7 31.6 33.8 45.7 48.6
Revenue growth (%) ** 14.2 3.3 11.9 7.2 6.2
adjusted EBITDA (€ million) **,*** 15.7 19.9 22.8 3.9 4.4 9.2 10.9 14.6 15.8
adjusted EBITDA margin (% of revenues) **,*** 29.7 32.9 36.5 25.8 26.4 29.3 32.2 31.9 32.5
adjusted EBIT (€ million) **,*** 15.3 19.5 22.4 3.8 4.3 9.0 10.6 14.3 15.4
adjusted EBIT margin (% of revenues) **,*** 28.9 32.3 35.8 25.1 25.8 28.7 31.5 31.3 31.8
 
Total shareholders’ equity (€ million) **** 73.7 84.4 95.6 98.9 8.0 11.4
Balance sheet total (€ million) **** 84.1 92.0 103.7 109.1 24.1 23.6
Equity ratio (% of balance sheet total) ** 87.7 91.7 92.1 90.7 33.0 48.3


*Audited, unless indicated otherwise.
** Unaudited.
*** Adjustment for one-time effects (H1 2020: 1,1 Mio. EUR / 9M 2020: 1,4 Mio. EUR) includes mainly costs for the corporate and organizational structuring of the PharmaSGP Group.
**** Figures 2017, 2018 and 2019: as of 31 December; figures Q1 2020: as of 31 March; figures H1: as of 30 June; figures 9M: as of 30 September.

Factsheet

Corporate Governance

Voting Rights Notifications
Directors' Dealings
Articles of Association
Statement of Compliance
Rules of Procedure of the Supervisory Board
Weitere Dokumente

May 11, 2021: Union Investment Privatfonds GmbH

October 08, 2020: Legal & General Group

July 06, 2020: Legal & General Group

June 25, 2020: Dr. Clemens Fischer (FUTRUE GmbH)

June 25, 2020: Madlena Hohlefelder (MVH Beteiligungs- und Beratungs-GmbH)

June 25, 2020: Grandeur Peak Global Advisors, LLC

June 22, 2020: Madlena Hohlefelder (MVH Beteiligungs- und Beratungs-GmbH)

June 22, 2020: Dr. Clemens Fischer (FUTRUE GmbH)

February 19, 2021: FUTRUE GmbH, Acquisition

June 26, 2020: MVH Beteiligungs- und Beratungs-GmbH, Granting of shares to members of the management board

June 26, 2020: FUTRUE GmbH, Granting of shares to members of the management board

June 26, 2020: Michael Rudolf, Acquisition

June 26, 2020: Natalie Weigand, Acquisition

June 25, 2020: FUTRUE GmbH, Disposal

June 25, 2020: MVH Beteiligungs- und Beratungs-GmbH, Disposal

June 22, 2020: FUTRUE GmbH, Disposal

June 22, 2020: MVH Beteiligungs- und Beratungs-GmbH, Disposal

June 22, 2020: FUTRUE GmbH, Securities lending

June 22, 2020: MVH Beteiligungs- und Beratungs-GmbH, Securities lending

Articles of Association (German language)

Statement of Compliance 2021 (current version, German language)

Archive

Statement of Compliance February 2021 (German language)

Statement of Compliance May 2020 (German language)

Rules of Procedure of the Supervisory Board (German language)

Another Tab Contents

Publications

Ad-hoc News
Corporate News
Financial Reports
Related Party Transactions
Other Documents

February 11, 2021: PharmaSGP Holding SE announces preliminary FY 2020 revenue and earnings trends after suspension of forecast

November 27, 2020: PharmaSGP Holding SE: Adjustment of full-year forecast 2020 due to expected weaker fourth quarter following COVID-19-related restrictions

June 18, 2020: PharmaSGP Holding SE sets offer price at €31.50 per share

May 18, 2021: PharmaSGP: Expected business development in Q1 2021

March 31, 2021: PharmaSGP: Revenue growth in 2020 despite declining markets

November 30, 2020: PharmaSGP publishes Q3 Interim Statement 2020

November 10, 2020: PharmaSGP continues its highly profitable growth course in the third quarter of 2020

September 30, 2020: PharmaSGP publishes H1 Report 2020 and confirms strong performance and positive outlook for the full year

September 10, 2020: PharmaSGP with strong revenue and EBIT growth and increased profitability in the first half of 2020

September 2, 2020: Sempora market study sees PharmaSGP as the winner in the corona crisis

September 1, 2020: PharmaSGP Holding SE strengthens Management Board for a consistent implementation of its growth strategy

June 18, 2020: PharmaSGP Holding SE valued at €378 million at IPO

June 18, 2020: PharmaSGP Holding SE considers a reduced volume for its IPO

June 8, 2020: PharmaSGP Holding SE sets its price range for ist envisaged IPO

May 27, 2020: PharmaSGP Holding SE plans Initial Public Offering

PharmaSGP Holding SE – Interim Statement Q1 2021

PharmaSGP Holding SE – Financial Statements 2020 (HGB) – German

PharmaSGP Holding SE – Annual Report 2020

PharmaSGP Holding SE – Interim Statement Q3 2020

PharmaSGP Holding SE – Half-year Financial Report 2020

PharmaSGP Group – IFRS Combined Financials First Quarter 2020

PharmaSGP Holding SE – Financial Statements 2019 (HGB)

PharmaSGP Group – IFRS Combined Financials 2017, 2018, 2019

In due time the contents of this page will be added.

April 1, 2021: Presentation Jefferies Pan European Mid Cap Conference

March 31, 2021: Presentation Preliminary results 2020

March 17, 2021: Presentation Berenberg DACH & Nordic Conference 2021

September 16, 2020: Presentation H1 2020 Results

June 8, 2021: Securities prospectus

June 8, 2020: Separate Summary

Annual General Meeting

Documents
Voting Results
Presentation
The Annual General Meeting of PharmaSGP Holding SE, based in Gräfelfing, Munich, will take place on 24 June 2021, 10am (CEST), as a virtual Annual General Meeting.
Here you can access the Annual General Meeting portal of PharmaSGP Holding SE:
Login AGM portal

Invitation to the Annual General Meeting 2021 including Agenda (German)

Annual Report 2020 of PharmaSGP Group - including Consolidated Financial Statements, the Combined Management Report and the Report of the Management Board on the Information according to sec. 289a and 315a HGB (German)

Annual Financial Statements 2020 of PharmaSGP Holding SE (German)

Report of the Supervisory Board for the 2020 Financial Year (German)

Annual Financial Statements 2019 of PharmaSGP Holding SE (formerly 184th Atrium V V SE) (German)

Opening Balance Sheet as of 21 November 2019 of PharmaSGP Holding SE (formerly 184th Atrium V V SE) (German)

Opening Balance Sheet of PharmaSGP Vertriebs GmbH (German)

Control and Profit and Loss Transfer Agreement between PharmaSGP Holding SE and PharmaSGP Vertriebs GmbH (German)

Report on the Control and Profit and Loss Transfer Agreement between PharmaSGP Holding SE and PharmaSGP Vertriebs GmbH (German)

Articles of Association of PharmaSGP Holding SE (German)

Information according to Table 3 of the Implementing Regulation (EU) 2018/1212 (English)

Sample Form for Authorization and Instructions to the Proxies of the Company (German)

Sample Form for Power of Attorney to Third Parties (German)

Sample Form for Revocation of Power of Attorney (German)

Explanatory Notes on Shareholders' Rights (German)

In due course, the contents of this page will be supplemented.
In due course, the contents of this page will be supplemented.

Hauptversammlung

This is a block of text. Double-click this text to edit it.

Contact

Contact details
Newsletter
Financial calendar
If you have any further questions, please do not hesitate to contact us. You can contact us via e-mail, mail, fax or directly by telephone. In addition, we offer you the opportunity to join our IR News Service in order to receive information from PharmaSGP promptly. For voting rights notifications to the company, please use the contact details below.

ADDRESS

PharmaSGP Holding SE
Lochhamer Schlag 21
82166 Gräfelfing

CONTACT PERSONS

Claudius Krause
Daniela Simonsen
cometis AG
+49 (0) 611 20 58 55 28+49 (0) 611 20 58 55 35
Fax: +49 (0) 611 20 58 55 66

Newsletter

We are happy to include you in our news service! Simply fill in the form below and you will receive information on the subject of Investor Relations.

Financial calendar

Mar 17, 2021: Berenberg DACH & Nordic Conference 2021 (virtual)
Mar 31, 2021: Publication of preliminary figures for the 2020 annual financial statements
Apr 01, 2021: Jefferies Pan-European Mid-Cap Virtual Conference
Apr 22, 2021: Publication of annual financial statements 2020

May 18, 2021: Publication of preliminary figures Q1 2021

May 18, 2021: Berenberg US Conference 2021 (virtual)

May 27, 2021: Publication of Quarterly Release Q1 2021

June 24, 2021: Annual General Meeting 2021 (virtual)

Sep 16, 2021: Publication of preliminary figures H1 2021
Sep 21, 2021: Berenberg and Goldman Sachs Tenth German Corporate Conference (virtual)
Sep 30, 2021: Publication of the 2021 half-year report
Nov 16, 2021: Publication of preliminary figures Q3 2021
Nov 16-18, 2021: 12th Annual Jefferies Global Healthcare Conference in London
Nov 22-24, 2021: Deutsches Eigenkapitalforum 2021
Nov 30, 2021: Publication of Quarterly Release Q3 2021

Dec 09, 2021: Berenberg European Conference

Financial calendar of 2020

Dec 03, 2020: Berenberg European Conference 2020 (Bagshot, UK)
Nov 30, 2020: Publication of Quarterly Release (Q3)
Nov 19, 2020: Jefferies Virtual London Healthcare Conference
Nov 17, 2020: Deutsches Eigenkapitalforum (online)
Nov 10, 2020: Publication of preliminary figures (Q3)
Oct 14, 2020: Berenberg Pan-European Discovery Conference USA 2020 (virtual)
Sep 30, 2020: Publication of the 2020 Half-year report
Sep 23, 2020: Ninth German Corporate Conference (online)
Sep 10, 2020: Publication of preliminary figures for 2020 half year
Aug 26, 2020: Berenberg Copenhagen Top Picks Seminar 2020 (online)
envelopemap-marker